Skip to main content
Top
Published in: Japanese Journal of Ophthalmology 5/2019

01-09-2019 | ANCA-Associated Vasculitis | Clinical Investigation

Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis)

Authors: Atsushi Yoshida, Meri Watanabe, Akira Okubo, Hidetoshi Kawashima

Published in: Japanese Journal of Ophthalmology | Issue 5/2019

Login to get access

Abstract

Purpose

We evaluated patient profiles, clinical features, associated systemic diseases, treatment modalities, and ocular complications in cases of scleritis and episcleritis.

Study design

Retrospective.

Methods

Clinical data of 128 patients referred to the ophthalmology clinic at Jichi Medical University Hospital during the 4-year period from April 2011 to March 2015, and diagnosed with scleritis or episcleritis were examined. Gender, average onset age, unilateral or bilateral manifestation, classification type, associated systemic diseases, and treatments were retrospectively investigated.

Results

The cohort consisted of 57 men and 71 women. Average onset age was 54.3 ± 17.4 years. Diffuse anterior scleritis was the most common type. It was noted in 43 (32.8%) patients, followed by episcleritis in 35 (27.3%), nodular anterior scleritis in 23 (18.0%), necrotizing anterior scleritis in 22 (17.2%), and posterior scleritis in 6 (4.7%). Eighteen (81.8%) of 22 patients with necrotizing anterior scleritis required some type of systemic medication, including corticosteroid, cyclophosphamide, cyclosporine, azathioprine, methotrexate, or rituximab administration. Forty (31.3%) had associated systemic diseases, which included 10 with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and 8 with rheumatoid arthritis (RA). Patients with ANCA-associated vasculitis had a tendency to develop scleritis first and had significantly worse visual prognoses compared to those with RA.

Conclusions

Approximately 30% of the patients with scleritis and episcleritis had complications involving systemic diseases, including ten patients with ANCA-associated vasculitis and 8 with RA. ANCA-associated vasculitis was more often diagnosed after scleritis and patients suffered poorer visual prognoses than those with RA.
Literature
1.
3.
go back to reference Akpek EK, Throne EJ, Qazi FA, Do DV, Jabs DA. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111:501–6.CrossRefPubMed Akpek EK, Throne EJ, Qazi FA, Do DV, Jabs DA. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111:501–6.CrossRefPubMed
4.
go back to reference McGavin DD, Williamson J, Forrester JV, Foulds WS, Buchanan WW, Dick WC, et al. Episcleritis and scleritis. A study of their clinical manifestation and association with rheumatoid arthritis. Br J Ophthalmol. 1976;60:192–226.CrossRefPubMedPubMedCentral McGavin DD, Williamson J, Forrester JV, Foulds WS, Buchanan WW, Dick WC, et al. Episcleritis and scleritis. A study of their clinical manifestation and association with rheumatoid arthritis. Br J Ophthalmol. 1976;60:192–226.CrossRefPubMedPubMedCentral
5.
go back to reference JCS Joint Working Group. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J. 2011;75:474–503.CrossRef JCS Joint Working Group. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J. 2011;75:474–503.CrossRef
6.
go back to reference Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80.CrossRefPubMed Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80.CrossRefPubMed
7.
go back to reference Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.CrossRefPubMedPubMedCentral Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.CrossRefPubMedPubMedCentral
8.
go back to reference Tanaka R, Kaburaki T, Ohtomo K, Takamoto M, Komae K, Numaga J, et al. Clinical characteristics and ocular complications of patients with scleritis in Japanese. Jpn J Ophthalmol. 2018;62:517–24.CrossRefPubMed Tanaka R, Kaburaki T, Ohtomo K, Takamoto M, Komae K, Numaga J, et al. Clinical characteristics and ocular complications of patients with scleritis in Japanese. Jpn J Ophthalmol. 2018;62:517–24.CrossRefPubMed
9.
go back to reference Ohguro N, Sonoda K, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432–5.CrossRefPubMed Ohguro N, Sonoda K, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432–5.CrossRefPubMed
10.
go back to reference Keino H, Watanabe T, Taki W, Nakashima C, Okada AA. Clinical features and visual outcomes of Japanese patients with scleritis. Br J Ophthalmol. 2010;94:1459–63.CrossRefPubMed Keino H, Watanabe T, Taki W, Nakashima C, Okada AA. Clinical features and visual outcomes of Japanese patients with scleritis. Br J Ophthalmol. 2010;94:1459–63.CrossRefPubMed
11.
go back to reference Berichicci L, Miserocchi E, Di Nicola M, La Spina C, Bandello F, Modorati G. Clinical features of patients with episcleritis and scleritis in an Italian tertiary care referral center. Eur J Ophthalmol. 2014;24:293–8.CrossRef Berichicci L, Miserocchi E, Di Nicola M, La Spina C, Bandello F, Modorati G. Clinical features of patients with episcleritis and scleritis in an Italian tertiary care referral center. Eur J Ophthalmol. 2014;24:293–8.CrossRef
12.
go back to reference Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, Tauber J, de la Maza SM, Foster CS. Clinical features and presentation of posterior scleritis: a report of 31 cases. Ocul Immunol Inflamm. 2014;22:203–7.CrossRefPubMed Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, Tauber J, de la Maza SM, Foster CS. Clinical features and presentation of posterior scleritis: a report of 31 cases. Ocul Immunol Inflamm. 2014;22:203–7.CrossRefPubMed
13.
go back to reference Oono S, Kurimoto T, Oku H, Mimura O. Adult T-cell leukemia presenting with episcleritis and secondary glaucoma. Jpn J Ophthalmol. 2009;53:70–1.CrossRefPubMed Oono S, Kurimoto T, Oku H, Mimura O. Adult T-cell leukemia presenting with episcleritis and secondary glaucoma. Jpn J Ophthalmol. 2009;53:70–1.CrossRefPubMed
14.
go back to reference Smith LK, Suhler EB, Lim LL, Choi D, Cioffi GA, Rosenbaum JT. Possible association between scleritis and lymphoma. Br J Ophthalmol. 2007;91:1728–9.CrossRefPubMed Smith LK, Suhler EB, Lim LL, Choi D, Cioffi GA, Rosenbaum JT. Possible association between scleritis and lymphoma. Br J Ophthalmol. 2007;91:1728–9.CrossRefPubMed
15.
go back to reference Hoang LT, Lim LL, Vaillant B, Choi D, Rosenbaum JT. Antineutrophil cytoplamic antibody-associated active scleritis. Arch Ophthalmol. 2008;126:651–5.CrossRefPubMed Hoang LT, Lim LL, Vaillant B, Choi D, Rosenbaum JT. Antineutrophil cytoplamic antibody-associated active scleritis. Arch Ophthalmol. 2008;126:651–5.CrossRefPubMed
16.
go back to reference Lin P, Bhullar SS, Tessler HH, Goldstein DA. Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am J Ophthalmol. 2008;145:463–71.CrossRefPubMed Lin P, Bhullar SS, Tessler HH, Goldstein DA. Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am J Ophthalmol. 2008;145:463–71.CrossRefPubMed
17.
go back to reference Kuroyanagi K, Sakai T, Yoshida K, Yamada A, Shiba T, Tsuneoka H. Necrotizing scleritis in a patient positive for both c- and p-ANCA without underlying systemic vasculitis. Jpn J Ophthalmol. 2011;55:581–2.CrossRefPubMed Kuroyanagi K, Sakai T, Yoshida K, Yamada A, Shiba T, Tsuneoka H. Necrotizing scleritis in a patient positive for both c- and p-ANCA without underlying systemic vasculitis. Jpn J Ophthalmol. 2011;55:581–2.CrossRefPubMed
18.
go back to reference Watkins AS, Kempen JH, Choi D, Liesegang TL, Pujari SS, Newcomb C, et al. Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Inform. 2010;3:12–9.CrossRef Watkins AS, Kempen JH, Choi D, Liesegang TL, Pujari SS, Newcomb C, et al. Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Inform. 2010;3:12–9.CrossRef
19.
go back to reference de la Maza SM, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995;102:687–92.CrossRef de la Maza SM, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995;102:687–92.CrossRef
20.
go back to reference Alrashidi S, Yousef YA, Krema H. Visaul loss from scleritis in C-ANCA microscopic polyangiitis. BMJ Case Rep. 2013;10:bcr2013009583. Alrashidi S, Yousef YA, Krema H. Visaul loss from scleritis in C-ANCA microscopic polyangiitis. BMJ Case Rep. 2013;10:bcr2013009583.
21.
go back to reference de la Maza SM, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Scleritis therapy. Ophthalmology. 2012;119:51–8.CrossRef de la Maza SM, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Scleritis therapy. Ophthalmology. 2012;119:51–8.CrossRef
22.
go back to reference de la Maza SM, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994;101:389–96.CrossRef de la Maza SM, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994;101:389–96.CrossRef
23.
go back to reference Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121:1885–91.CrossRefPubMed Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121:1885–91.CrossRefPubMed
24.
go back to reference McCluskey P, Wakefield D. Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust N Z J Ophthalmol. 1991;19:211–5.CrossRefPubMed McCluskey P, Wakefield D. Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust N Z J Ophthalmol. 1991;19:211–5.CrossRefPubMed
Metadata
Title
Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis)
Authors
Atsushi Yoshida
Meri Watanabe
Akira Okubo
Hidetoshi Kawashima
Publication date
01-09-2019
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 5/2019
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-019-00674-7

Other articles of this Issue 5/2019

Japanese Journal of Ophthalmology 5/2019 Go to the issue